Katherine Bach Kalin Acquires 63,400 Shares of SELLAS Life Sciences Group (NASDAQ:SLS) Stock

Director Katherine Bach Kalin acquired 63,400 shares of SELLAS Life Sciences Group, increasing her ownership by 154.63%. The shares were bought at $1.59 each, totaling $100,806. Post-transaction, she owns 104,400 shares valued at $165,996. The purchase was disclosed in an SEC filing. SELLAS Life Sciences Group focuses on cancer immunotherapies, with its lead product in Phase 3 trials for leukemia. The stock has a market cap of $207.97 million and a consensus rating of "Hold" with a target price of $7.00.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) Director Katherine Bach Kalin acquired 63,400 shares of the stock in a transaction that occurred on Wednesday, November 19th. The stock was purchased at an average price of $1.59 per share, with a total value of $100,806.00. Following the transaction, the director owned 104,400 shares in the company, valued at $165,996. This represents a 154.63% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

SELLAS Life Sciences Group Stock Performance

NASDAQ SLS opened at $1.46 on Friday. The stock has a market cap of $207.97 million, a price-to-earnings ratio of -4.56 and a beta of 2.64. SELLAS Life Sciences Group, Inc. has a 52-week low of $0.77 and a 52-week high of $2.48. The business has a 50 day simple moving average of $1.76 and a 200 day simple moving average of $1.76.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. On average, analysts predict that SELLAS Life Sciences Group, Inc. will post -0.57 EPS for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $7.00.

View Our Latest Research Report on SLS

Institutional Trading of SELLAS Life Sciences Group

Hedge funds have recently bought and sold shares of the business. Virtu Financial LLC lifted its stake in SELLAS Life Sciences Group by 30.9% during the 1st quarter. Virtu Financial LLC now owns 53,861 shares of the company's stock valued at $58,000 after acquiring an additional 12,706 shares in the last quarter. Anson Funds Management LP lifted its stake in SELLAS Life Sciences Group by 535.7% in the first quarter. Anson Funds Management LP now owns 7,579,095 shares of the company's stock valued at $8,185,000 after purchasing an additional 6,386,829 shares during the last quarter. Blair William & Co. IL bought a new position in shares of SELLAS Life Sciences Group during the 2nd quarter worth $35,000. Simon Quick Advisors LLC bought a new stake in SELLAS Life Sciences Group during the 2nd quarter valued at $44,000. Finally, ProShare Advisors LLC purchased a new position in SELLAS Life Sciences Group during the 2nd quarter valued at about $43,000. Institutional investors and hedge funds own 17.38% of the company's stock.

SELLAS Life Sciences Group Company Profile

(Get Free Report)

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.

Five stocks we like better than SELLAS Life Sciences Group
How to Invest in the Best Canadian Stocks
3 Big Tech Stocks Sliding: What’s Behind the Drop?
Should You Add These Warren Buffett Stocks to Your Portfolio?
Wall Street Sees a Winner in Take-Two Stock. Should You?
The Significance of Brokerage Rankings in Stock Selection
Datavault AI Just Raised Guidance by 400%—Are You Paying Attention?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in SELLAS Life Sciences Group Right Now?

Before you consider SELLAS Life Sciences Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.

While SELLAS Life Sciences Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here